DDW’s Megan Thomas speaks to Dr Lucas Thompson, Senior Director of Research at Tune Therapeutics, about the advancements in cell line development and how biotechnologies can enhance the precision and efficiency of therapeutic protein production. MT: What are the benefits cell line development is bringing to biopharmaceutical developers? LT: For… Read More
Epigenome editing company Tune Therapeutics has announced the completion of over $175 million in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution Foundation. Tune Co-Founder Dr Charles Gersbach, whose research at Duke University formed the basis for Tune’s TEMPO epi-editing platform, commented: “Tune has… Read More
Epigenome editing company Tune Therapeutics has showcased new data at the American Association for the Study of Liver Diseases (AASLD) conference, in support of its drive to develop a lasting, functional cure for chronic Hepatitis B Virus (HBV). Tune presented its lead HBV programme at the 2023 iteration of the… Read More
Nathan Yee, Senior Director of CMC Portfolio Strategy at Tune Therapeutics, and Lucas Thompson, Senior Director of Research at Tune Therapeutics, discuss the opportunities and challenges in cell therapy. Cell therapy is a transformative medical approach that harnesses living cells as therapeutic agents and has demonstrated the potential to address… Read More
